By Sandeep Kumar Singh Ph.D. in Biotechnology, Amarish Kumar Yadav, Burkhard Poeggeler PhD, George Perry
Genome Editing for Neurodegenerative Diseases: From Concept to Clinical Trials examines recent advances in neurodegenerative disease research and clinical challenges in practical applications. With an emphasis on genome editing tools such as ZFNs, TALENSs and CRISPR-Cas, this book sheds light on the possibilities to counteract genetic and neurodegenerative diseases. It will be of interest to researchers in neuroscience and biopharmaceuticals, as well as clinicians specializing in neurodegenerative diseases.
Covers basic mechanisms of genome-editing tools and their therapeutic potential
Highlights current research progress and the therapeutic strategies to use genome-editing tools against neurodegenerative diseases
Includes research on genome-editing tool development from the basic concept to clinical trials
Product Details
Publisher : Academic Press; 1st edition (November 1, 2024)
Language : English
Paperback : 260 pages
ISBN-10 : 044323826X
ISBN-13 : 978-0443238260
Lippincott's Concise Illustrated Anatomy: Volume 1: Back, Upper Limb and Lower Limb
Medicines, Ethics and Practice: The Professional Guide for Pharmacists
Pharmacology of Ocular Therapeutics (PDF)
Sexually Transmitted Infections: Diagnosis, Management, and Treatment
Spencer's Pathology of the Lung 6th, 2 Part Set
Head and Neck Cancer: An Evidence-Based Team Approach
The Licensing Exam Review Guide in Nursing Home Administration, Seventh Edition
History of Infectious Disease Pandemics in Urban Societies
Practical Manual of Histology (PDF)
Small Animal Soft Tissue Surgery
Dynamic Ophthalmic Ultrasonography: A Video Atlas for Ophthalmologists and Imaging Technicians (PDF)
Field Guide to Wilderness Medicine 4th
Essentials of Nuclear Medicine Imaging 6th
Seldin and Giebisch's The Kidney, Fifth Edition: Physiology & Pathophysiology
Ocular Surface Disease: Cornea, Conjunctiva and Tear Film
Telemedicine and Electronic Medicine 


Reviews
There are no reviews yet.